<DOC>
	<DOCNO>NCT02624570</DOCNO>
	<brief_summary>The purpose study provide access Midostaurin gather additional safety data combination Midostaurin standard care adult patient newly diagnose Fms-like tyrosine kinase receptor ( FLT3 ) mutate Acute Myeloid Leukemia ( AML ) eligible standard induction consolidation chemotherapy .</brief_summary>
	<brief_title>Midostaurin Access Program Newly Diagnosed FLT3 ( ITD TKD ) Mutated AML Adult Patients Eligible Standard Induction Consolidation Chemotherapy .</brief_title>
	<detailed_description>The purpose study provide Midostaurin ( study drug ) treatment newly diagnose FLT3 mutate ( ITD TKD ) AML adult patient ( 18 year old ) eligible standard standard induction ( cytarabine + daunorubicin/Idarubicin ) consolidation ( cytarabine ) chemotherapy .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>4'-N-benzoylstaurosporine</mesh_term>
	<mesh_term>Staurosporine</mesh_term>
	<criteria>Written informed consent must obtain prior screen procedure . Patients must meet Patient able communicate well investigator , understand comply requirement study . Patients must 18 year age old ; elderly patient must fit receive intensive induction consolidation chemotherapy Patients must document FLT3 mutation ( ITD TKD ) Patients must ECOG Performance Status ≤ 2 Patients must document unequivocal diagnosis AML accord WHO 2008 classification ( &gt; 20 % blast bone marrow and/or peripheral blood ) , exclude M3 ( acute promyelocytic leukemia ) . Patients require intrathecal chemotherapy must minimum washout 48 hour prior first dose midostaurin AML patient history antecedent treatment myelodysplasia ( MDS ) , e.g . azacitidine decitabine , remain eligible treatment study . These agent must discontinue period least 30 day 5 halflives drug ( whichever great ) midostaurin administer . Secondary AML , e.g . patient antecedent history treatment prior malignancy Patients must follow laboratory value ( Direct Bilirubin ≤ 2.5 x ULN , Serum Creatinine ≤ 2.5 x ULN ) Patients eligible study must meet following criterion : Prior therapy AML follow exception : ( emergency leukapheresis , emergency treatment hyperleukocytosis hydroxyurea ≤ 5 day , cranial RT CNS leukostasis ( one dose ) , growth factor/cytokine support ) Patients LVEF le 45 % ( echocardiogram MUGA ) symptomatic congestive heart failure , Class III IV accord New York Heart Association ( NYHA ) classification Patients uncontrolled illness , include , limited , acute chronic pancreatitis uncontrolled infection QTc &gt; 500 msec screen ECG . History hypersensitivity drug metabolites similar chemical class IMP . Participation prior investigational interventional ( drug ) study administration investigational product within 30 day 5 halflives investigational product , whichever longer . Women childbearing potential , defined woman physiologically capable become pregnant , include woman whose career , lifestyle , sexual orientation precludes intercourse male partner woman whose partner sterilize vasectomy mean , UNLESS use two birth control method . Sexually active male father child study upto 5 month follow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>AML</keyword>
	<keyword>FLT3</keyword>
	<keyword>ITD</keyword>
	<keyword>TKD</keyword>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>induction</keyword>
	<keyword>consolidation</keyword>
	<keyword>continuation</keyword>
	<keyword>EAP</keyword>
	<keyword>ETP</keyword>
	<keyword>midostaurin</keyword>
	<keyword>PKC412</keyword>
</DOC>